---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-023083"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T07:09:39.936920+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sana Biotechnology reports Q4 net loss $88.1M; cash $205M; raises $190M in Feb; 40-60 patients in 2024

## Summary
- Q4 2023 net loss $88.1M ($0.45/share); full year net loss $283.3M ($1.46/share).
- Cash $205.2M at Dec 31, 2023; Feb 2024 offering raised $189.8M gross proceeds to fund pipeline.
- Plans to treat 40-60 patients in 2024 across 4 trials in oncology, autoimmune, and type 1 diabetes.
- Early SC291 data safe, immune evasion, early efficacy; IND cleared for SC291 in autoimmune and SC262 in B-cell malignancies.
- Appointed Doug Williams President R&D, Gary Meininger CMO; expects 2024 operating burn <$200M.

## SEC filing metadata
- accession: 0000950170-24-023083
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000095017024023083/0000950170-24-023083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000095017024023083/sana-20240229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-023083
- JSON: https://secwatch.observer/filing/0000950170-24-023083.json
- Plain text: https://secwatch.observer/filing/0000950170-24-023083.txt

## Key facts
- Earnings Releases
  Sana Biotechnology, Inc. reported financial results for the quarter and year ended December 31, 2023.
  - Period: the quarter and year ended December 31, 2023
  - Result: reported results
  source text: On February 29, 2024, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770121/000095017024023083/0000950170-24-023083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.